Charles River Laboratories
251 Ballardvale Street
Wilmington
Massachusetts
01887
United States
Tel: 877-274-8371
Website: http://www.criver.com/
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
415 articles with Charles River Laboratories
-
Charles River Laboratories Announces First-Quarter 2022 Results
5/4/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2022. For the quarter, revenue was $913.9 million, an increase of 10.8% from $824.6 million in the first quarter of 2021.
-
Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets
4/27/2022
Charles River Laboratories International, Inc. (NYSE: CRL) and Valo Health, Inc (“Valo”) have launched Logica TM , an artificial intelligence (AI) powered drug solution that directly translates clients’ biological insights into optimized preclinical assets.
-
Charles River Laboratories Publishes 2021 Corporate Citizenship Report
4/7/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the publication of its 2021 Corporate Citizenship Report.
-
Charles River Laboratories Acquires Explora BioLabs
4/6/2022
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has acquired Explora BioLabs Holdings, Inc.
-
Charles River Laboratories to Appoint Flavia H. Pease as Chief Financial Officer
3/28/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it will appoint Flavia H. Pease as its next Chief Financial Officer, succeeding David R. Smith, who previously announced on January 11th that he intends to retire.
-
Hera BioLabs Announces Exclusive Global License With Charles RiverCharles River will license Hera's SRG rat (OncoRat), the first highly immunocompromised rat model
3/16/2022
Hera BioLabs, an innovative service and technology provider with novel genetic engineering products, has announced a collaboration with Charles River Laboratories, International Inc. for a global license agreement to commercialize Hera's SRGTM rat (OncoRat®).
-
Charles River Laboratories Announces Fourth-Quarter and Full-Year 2021 Results
2/16/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2021 and reaffirmed guidance for 2022.
-
Charles River Laboratories Announces Wind Contract with Repsol for European Operations
2/3/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a wind energy contract with Repsol to address the entirety of the Company’s European power requirements with renewable energy by 2023.
-
Charles River Expands Strategic Partnership With SAMDI Tech
1/27/2022
Charles River Laboratories International, Inc . (NYSE: CRL) today announced the expansion of their strategic partnership with Chicago, Illinois-based SAMDI Tech, Inc.
-
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call
1/20/2022
Charles River Laboratories Schedules Fourth-Quarter 2021 Earnings Release and Conference Call.
-
Charles River Laboratories Announces Chief Financial Officer Retirement and Transition Plan
1/11/2022
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a retirement and transition plan for its Chief Financial Officer.
-
Charles River Laboratories to Participate in Upcoming Investor Conferences
11/16/2021
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at two upcoming investor conferences, including: Jefferies London Healthcare Conference on Thursday, November 18th
-
Charles River Laboratories Promotes Birgit Girshick to Chief Operating Officer
11/11/2021
Charles River Laboratories International, Inc. (NYSE:CRL) today announced that Birgit Girshick has been promoted to the position of Chief Operating Officer, effective immediately.
-
Charles River Laboratories Announces Third-Quarter 2021 Results
11/3/2021
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2021. For the quarter, revenue was $895.9 million, an increase of 20.5% from $743.3 million in the third quarter of 2020.
-
Charles River Laboratories Schedules Third-Quarter 2021 Earnings Release and Conference Call
10/13/2021
Charles River Laboratories International, Inc. (NYSE: CRL) will release third-quarter 2021 financial results on Wednesday, November 3rd , before the market opens.
-
The Jackson Laboratory Announces Acquisition of Charles River Laboratories Japan
10/13/2021
The Jackson Laboratory, a U.S.-based nonprofit biomedical research institution, announced that it has acquired Charles River Laboratories Japan’s Research Models & Services business as a wholly owned subsidiary.
-
Charles River Laboratories Announces Two Divestitures
10/13/2021
Charles River Laboratories International, Inc. announced that it has divested its Research Models and Services operations in Japan and its gene therapy CDMO site in Sweden in two separate transactions.
-
Charles River Launches First Annual Healthcare Collaboration Report
9/20/2021
Charles River Laboratories International, Inc. (NYSE: CRL) today released the results from its first annual Healthcare Collaboration Report
-
Charles River Laboratories Announces Second-Quarter 2021 Results
8/4/2021
Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2021. For the quarter, revenue was $914.6 million, an increase of 34.0% from $682.6 million in the second quarter of 2020.
-
Charles River Laboratories Schedules Second-Quarter 2021 Earnings Release and Conference Call
7/13/2021
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2021 financial results on Wednesday, August 4 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 4 th , at 9:30 a.m. ET.